glp-1 receptor agonist antipsychotic weight gain study Efficacy and Safety of Agonists for the Management of Antipsychotic-Induced The Weight-loss Effect of GLP-1RAs

Am J Physiol Endocrinol Metab 2016

Oral semaglutide has been approved and recently marketed in Spain following evidence from the Phase 3 clinical trial program Peptide InnOvatioN for Early diabEtes tReatment (PIONEER)

Leech, C

An optimized GLP-1/CCK fusion had enhanced efficacy to lower body weight in obese rodents relative to mono-agonist controls and their co-administration [946,947]

So between these long periods of not eating and eating a ton, they must have some way to keep their metabolism running smoothly and their blood sugar balanced

Consequently, optimizing the management in KTRs with DM is of paramount importance to improve long term outcomes